Press "Enter" to skip to content

Merck, Pfizer drug combo extends kidney cancer survival – study

A combination of Merck & Co’s immunotherapy Keytruda and Pfizer Inc’s Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday.

Original source:

Also Read:   Chinese province reports 11 new virus cases from Iran flights: state media